View in EDS HTML Full Text PDF Full Text

Time to progression is a simple and robust prognostic factor for survival in relapsed or refractory diffuse large B-cell lymphoma.

Saved in:
Bibliographic Details
Title: Time to progression is a simple and robust prognostic factor for survival in relapsed or refractory diffuse large B-cell lymphoma.
Authors: Cheng CL; Department of Internal Medicine, National Taiwan University Hospital, No. 7, Chung-Shan South Road, Taipei 10002, Taiwan., Huang TC; Division of Hematology, Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan., Tuan YH; Division of Hematology, Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan., Liang JF; Clinical Trial Center, Department of Medical Research, National Taiwan University Hospital, Taipei, Taiwan., Wang SM; Clinical Trial Center, Department of Medical Research, National Taiwan University Hospital, Taipei, Taiwan., Chen LC; Roche Product Ltd, Taipei, Taiwan., Wu YC; Roche Product Ltd, Taipei, Taiwan., Chang CH; Clinical Trial Center, Department of Medical Research, National Taiwan University Hospital, Taipei, Taiwan.
Source: Therapeutic advances in medical oncology [Ther Adv Med Oncol] 2025 Dec 04; Vol. 17, pp. 17588359251396884. Date of Electronic Publication: 2025 Dec 04 (Print Publication: 2025).
Publication Type: Journal Article
Journal Info: Publisher: Sage Country of Publication: England NLM ID: 101510808 Publication Model: eCollection Cited Medium: Print ISSN: 1758-8340 (Print) Linking ISSN: 17588340 NLM ISO Abbreviation: Ther Adv Med Oncol Subsets: PubMed not MEDLINE
Database: MEDLINE Ultimate
Full text is not displayed to guests.
FullText Links:
  – Type: pdflink
Text:
  Availability: 1
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 41362588
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Time to progression is a simple and robust prognostic factor for survival in relapsed or refractory diffuse large B-cell lymphoma.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Cheng+CL%22">Cheng CL</searchLink>; Department of Internal Medicine, National Taiwan University Hospital, No. 7, Chung-Shan South Road, Taipei 10002, Taiwan.<br /><searchLink fieldCode="AU" term="%22Huang+TC%22">Huang TC</searchLink>; Division of Hematology, Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan.<br /><searchLink fieldCode="AU" term="%22Tuan+YH%22">Tuan YH</searchLink>; Division of Hematology, Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan.<br /><searchLink fieldCode="AU" term="%22Liang+JF%22">Liang JF</searchLink>; Clinical Trial Center, Department of Medical Research, National Taiwan University Hospital, Taipei, Taiwan.<br /><searchLink fieldCode="AU" term="%22Wang+SM%22">Wang SM</searchLink>; Clinical Trial Center, Department of Medical Research, National Taiwan University Hospital, Taipei, Taiwan.<br /><searchLink fieldCode="AU" term="%22Chen+LC%22">Chen LC</searchLink>; Roche Product Ltd, Taipei, Taiwan.<br /><searchLink fieldCode="AU" term="%22Wu+YC%22">Wu YC</searchLink>; Roche Product Ltd, Taipei, Taiwan.<br /><searchLink fieldCode="AU" term="%22Chang+CH%22">Chang CH</searchLink>; Clinical Trial Center, Department of Medical Research, National Taiwan University Hospital, Taipei, Taiwan.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22101510808%22">Therapeutic advances in medical oncology</searchLink> [Ther Adv Med Oncol] 2025 Dec 04; Vol. 17, pp. 17588359251396884. <i>Date of Electronic Publication: </i>2025 Dec 04 (<i>Print Publication: </i>2025).
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Sage%22">Sage </searchLink><i>Country of Publication: </i>England <i>NLM ID: </i>101510808 <i>Publication Model: </i>eCollection <i>Cited Medium: </i>Print <i>ISSN: </i>1758-8340 (Print) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2217588340%22">17588340 </searchLink><i>NLM ISO Abbreviation: </i>Ther Adv Med Oncol <i>Subsets: </i>PubMed not MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=41362588
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1177/17588359251396884
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 17588359251396884
    Titles:
      – TitleFull: Time to progression is a simple and robust prognostic factor for survival in relapsed or refractory diffuse large B-cell lymphoma.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Cheng CL
      – PersonEntity:
          Name:
            NameFull: Huang TC
      – PersonEntity:
          Name:
            NameFull: Tuan YH
      – PersonEntity:
          Name:
            NameFull: Liang JF
      – PersonEntity:
          Name:
            NameFull: Wang SM
      – PersonEntity:
          Name:
            NameFull: Chen LC
      – PersonEntity:
          Name:
            NameFull: Wu YC
      – PersonEntity:
          Name:
            NameFull: Chang CH
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 04
              M: 12
              Text: 2025 Dec 04
              Type: published
              Y: 2025
          Identifiers:
            – Type: issn-print
              Value: 1758-8340
          Numbering:
            – Type: volume
              Value: 17
          Titles:
            – TitleFull: Therapeutic advances in medical oncology
              Type: main
ResultId 1